Showing results (131-140 of 209) with videos related to

Sort By:
Pageof 21
Oncotargets and Therapy|December 3, 2010
Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristicsKimbach Tran Carpiuc, Gianantonio Rosti, Fausto Castagnetti, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 6, 2020
Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database AnalysisCourtney Johnson, Jennifer Stephens, Christopher Walker, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 18, 2020
Cost-Minimization Analysis of Dexmedetomidine Compared to Other Sedatives for Short-Term Sedation During Mechanical Ventilation in the United StatesJyoti Aggarwal, Jacqueline Lustrino, Jennifer Stephens, et al.
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
Treatment patterns in a real-world cohort of patients with Wilson disease in the United StatesValentina Medici, Nehemiah Kebede, Jennifer Stephens, et al.
Frontiers in Pediatrics|October 14, 2024
Trust of inpatient physicians among parents of children with medical complexity: a qualitative studyTammie Dewan, Andrea Whiteley, Lyndsay Jerusha MacKay, et al.
Current Medical Research and Opinion|May 11, 2005
Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health AdministrationMonica Schaefer, Melissa DeLattre, Xin Gao, et al.
Social Work|August 1, 2014
Descriptive analysis of individual and community factors among African American youths in urban public housingVon E Nebbitt, James Herbert Williams, Margaret Lombe, et al.
Antimicrobial Resistance and Infection Control|February 27, 2019
Value of hospital antimicrobial stewardship programs [ASPs]: a systematic reviewDilip Nathwani, Della Varghese, Jennifer Stephens, et al.
Future Oncology (London, England)|March 31, 2022
Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropeniaPaul Cornes, John Kelton, Rongzhe Liu, et al.
Pageof 21